

May 12, 2021

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attention: Dillon Hagijs
Irene Paik
Christie Wong
Vanessa Robertson

Re: **Vera Therapeutics, Inc.**
Registration Statement on Form S-1
Registration No. 333-255492

Acceleration Request

Requested Date: May 13, 2021

Requested Time: 4:30 PM, Eastern Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), Jefferies LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters, hereby join Vera Therapeutics, Inc. in requesting that the Securities and Exchange Commission (the “**Commission**”) take appropriate action to cause the Registration Statement on Form S-1, as amended (File No. 333-255492) (the “**Registration Statement**”) to become effective on May 13, 2021, at 4:30 PM, Eastern Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

[Signature Page Follows]

Very truly yours,

Jefferies LLC

By: /s/ Michael Brinkman

Name: Michael Brinkman

Title: Managing Director

Cowen and Company, LLC

By: /s/ Bill Follis

Name: Bill Follis

Title: Managing Director

Evercore Group L.L.C.

By: /s/ Ed Baxter

Name: Ed Baxter

Title: Senior Managing Director

cc: Jonathan Wolter, Vera Therapeutics, Inc.
Heidi Mayon, Goodwin Procter LLP
Jesse Nevarez, Goodwin Procter LLP
Jodie Bourdet, Cooley LLP
Carlton Fleming, Cooley LLP

[Signature Page to Acceleration Request]